Hormesis in cancer immunology: Does the quantity of an immune reactant matter?

OncoImmunology

Volumn 3, Issue 6, 2014, Pages

  Pearce, Oliver M T ^a   Läubli, Heinz ^a   Bui, Jack ^a   Varki, Ajit ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibodies; Dose response; Hormesis; Immune cell polarization; Immune response curve; Immunotherapy

Indexed keywords

RITUXIMAB;

ADAPTIVE IMMUNITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL INFILTRATION; HORMESIS; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; MACROPHAGE; NATURAL KILLER CELL; NONHUMAN; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84906505334     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.29312     Document Type: Article

References (10)

1. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480:480-9; PMID:22193102; http://dx.doi.org/10.1038/ nature10673
2. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci 2012; 125:5591-6; PMID:23420197; http://dx.doi. org/10.1242/jcs.116392
3. Andreu P, Johansson M, Affara NI, Pucci F, Tan T, Junankar S, Korets L, Lam J, Tawfik D, DeNardo DG, et al. FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 2010; 17:121-34; PMID:20138013; http://dx.doi. org/10.1016/j.ccr.2009.12.019
4. Wu X, Ragupathi G, Panageas K, Hong F, Livingston PO. Accelerated tumor growth mediated by sublytic levels of antibody-induced complement activation is associated with activation of the PI3K/AKT survival pathway. Clin Cancer Res 2013; 19:4728-39; PMID:23833306; http://dx.doi.org/10.1158/1078-0432.CCR-13-0088
5. Pearce OM, Läubli H, Verhagen A, Secrest P, Zhang J, Varki NM, Crocker PR, Bui JD, Varki A. Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies. Proc Natl Acad Sci U S A 2014; 111:5998-6003; PMID:24711415; http:// dx.doi.org/10.1073/pnas.1209067111
6. Prehn RT. The initial immune reaction to a new tumor antigen is always stimulatory and probably necessary for the tumor's growth. Clin Dev Immunol 2010; 2010: http://dx.doi.org/10.1155/2010/851728; PMID:20811480
7. Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol 2007; 19:203-8; PMID:17292599; http://dx.doi. org/10.1016/j.coi.2007.02.001
8. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, Mantovani A. Macrophage polarization in tumour progression. Semin Cancer Biol 2008; 18:349-55; PMID:18467122; http://dx.doi.org/10.1016/j. semcancer.2008.03.004
9. Calabrese EJ. Hormesis and medicine. Br J Clin Pharmacol 2008; 66:594-617; PMID:18662293
10. rd, Richards P, Greco FA. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000; 95:3052-6; PMID:10807768